IRIS
VENDITTI, ADRIANO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 71.594
EU - Europa 9.701
AS - Asia 9.402
SA - Sud America 1.383
AF - Africa 204
OC - Oceania 52
Continente sconosciuto - Info sul continente non disponibili 24
Totale 92.360
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 71.273
SG - Singapore 4.242
IT - Italia 2.483
CN - Cina 1.976
DE - Germania 1.917
RU - Federazione Russa 1.237
BR - Brasile 1.102
HK - Hong Kong 936
UA - Ucraina 921
VN - Vietnam 755
IE - Irlanda 754
GB - Regno Unito 561
FR - Francia 555
FI - Finlandia 335
KR - Corea 316
JP - Giappone 303
NL - Olanda 209
SE - Svezia 204
IN - India 198
CA - Canada 185
PL - Polonia 109
AR - Argentina 100
ES - Italia 86
ID - Indonesia 85
BD - Bangladesh 84
MX - Messico 84
AT - Austria 81
ZA - Sudafrica 73
TR - Turchia 65
IQ - Iraq 52
EG - Egitto 50
IR - Iran 47
AU - Australia 46
PH - Filippine 46
BE - Belgio 43
EC - Ecuador 41
PK - Pakistan 39
UZ - Uzbekistan 38
CO - Colombia 30
SA - Arabia Saudita 29
TH - Thailandia 29
PE - Perù 27
CH - Svizzera 25
CZ - Repubblica Ceca 25
VE - Venezuela 25
CL - Cile 23
MY - Malesia 22
LT - Lituania 20
RO - Romania 20
MA - Marocco 19
IL - Israele 17
PY - Paraguay 17
DO - Repubblica Dominicana 15
TW - Taiwan 15
EU - Europa 14
TN - Tunisia 14
AE - Emirati Arabi Uniti 13
AL - Albania 13
JO - Giordania 13
NP - Nepal 13
GR - Grecia 11
HR - Croazia 11
DK - Danimarca 10
PT - Portogallo 10
BG - Bulgaria 9
KG - Kirghizistan 9
KZ - Kazakistan 9
BO - Bolivia 8
KE - Kenya 8
LB - Libano 8
SN - Senegal 8
UY - Uruguay 8
A2 - ???statistics.table.value.countryCode.A2??? 7
AZ - Azerbaigian 7
DZ - Algeria 7
HN - Honduras 7
JM - Giamaica 7
NG - Nigeria 7
RS - Serbia 7
CR - Costa Rica 6
SK - Slovacchia (Repubblica Slovacca) 6
AO - Angola 5
HU - Ungheria 5
MD - Moldavia 5
NO - Norvegia 5
NZ - Nuova Zelanda 5
PS - Palestinian Territory 5
QA - Qatar 5
BJ - Benin 4
BY - Bielorussia 4
CY - Cipro 4
KW - Kuwait 4
LU - Lussemburgo 4
BA - Bosnia-Erzegovina 3
BH - Bahrain 3
EE - Estonia 3
GE - Georgia 3
GT - Guatemala 3
LK - Sri Lanka 3
SI - Slovenia 3
Totale 92.315
Salva come PNG Salva come JPEG
Città #
Woodbridge 19.550
Wilmington 17.824
Houston 14.884
Singapore 2.413
Fairfield 2.145
Ashburn 1.563
Ann Arbor 1.556
Chandler 1.429
San Jose 1.186
Hong Kong 910
Seattle 861
Jacksonville 798
Cambridge 747
Beijing 720
Dublin 697
Rome 609
Dearborn 528
New York 525
Medford 495
Santa Clara 383
Dallas 374
The Dalles 334
Los Angeles 317
Milan 277
Council Bluffs 261
Tokyo 256
Ho Chi Minh City 241
Lawrence 231
Zhengzhou 212
Lauterbourg 187
Buffalo 180
Moscow 166
Hanoi 159
Boardman 123
San Diego 106
São Paulo 106
Munich 103
Helsinki 100
Orem 90
London 87
Menlo Park 82
Chicago 80
Mülheim 80
Brooklyn 79
Redwood City 77
Warsaw 72
Nuremberg 70
Shanghai 70
Creede 69
Bologna 63
North Bergen 63
Montreal 60
Engelhard 59
Hefei 57
Jakarta 56
Frankfurt am Main 51
Johannesburg 50
Nanjing 50
Lappeenranta 47
Atlanta 46
Guangzhou 46
Toronto 46
Redondo Beach 45
Chennai 44
Stockholm 42
Florence 41
Phoenix 41
San Francisco 41
Da Nang 40
Norwalk 40
Rio de Janeiro 39
Amsterdam 37
University Park 37
Brussels 36
Naples 35
Denver 32
Kunming 32
Falls Church 30
Verona 30
Boston 29
Mountain View 29
Paris 29
Poplar 29
Vienna 29
Ankara 28
Center 28
Columbus 28
Manchester 28
Mumbai 28
Seoul 28
Haiphong 26
Palo Alto 26
Turin 25
Del Norte 24
Madrid 23
Bari 22
Mexico City 21
Wuhan 21
Belo Horizonte 20
Hangzhou 20
Totale 76.289
Salva come PNG Salva come JPEG
Nome #
La leucemia mieloide acuta nell’anziano. 1.012
Idiopathic thrombocytopenic purpura: current concepts in pathophysiology and management. 663
Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia 627
BRCA1, PARP1 and γH2AX in acute myeloid leukemia: Role as biomarkers of response to the PARP inhibitor olaparib. 545
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 542
A microgranular variant of acute promyelocytic leukemia with atypical morpho-cytochemical features and an early myeloid immunophenotype 532
CD7 expression in acute myeloid leukemia 529
Enumeration of CD34+ hematopoietic progenitor cells for clinical transplantation: comparison of three different methods 517
AML-M0: A review of laboratory features and proposal of new diagnostic criteria 512
A novel t(11;12)(q23-24;q24) in a case of minimally-differentiated acute myeloid leukemia (AML-M0) 509
An allele-specific RT-PCR assay to detect type A mutation of the nucleophosmin-1 gene in acute myeloid leukemia 504
Minimally differentiated acute myeloid leukemia (AML-MO): a distinct clinico-biologic entity with poor prognosis 497
Analysis of the expression of adhesion molecules on CD34+ progenitors from bone marrow, umbilical cord blood and G-CSF mobilized peripheral blood 497
All-trans-retinoic acid plus low-doses of cytarabine for the treatment of poor-risk acute myeloid leukemias 495
Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantation 494
A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias 494
A phase-II trial of all trans retinoic acid and low-dose cytosine arabinoside for the treatment of high-risk myelodysplastic syndromes 494
Positive selection of CD34+ cells by immunoadsorption: factors affecting the final yield and hematopoietic recovery in patients with hematological malignancies and solid tumors 489
Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) 482
Clinical significance of CD38 expression in chronic lymphocytic leukemia 476
Acute megakaryoblastic leukemia: experience of GIMEMA trials 475
Comparison between conventional banding analysis and FISH screening with an AML specific set of probes in 260 patients 474
Red blood cell depletion of cord blood using hydroxyethylstarch double sedimentation: analysis of 40 cases 473
Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients 472
The kinetics of reduction of minimal residual disease impacts on duration of response and survival of patients with acute myeloid leukemia. 470
M4 acute myeloid leukemia: the role of eosinophilia and cytogenetics in treatment response and survival. The GIMEMA experience. 470
Autologous stem-cell transplantation for patients with acute myeloid leukemia aged over 60 yr 470
Biological profile of 23 cases of minimally differentiated acute myeloid leukemia (AML-MO) and its clinical implications 470
Multiparametric analysis for the enumeration of CD34+ cells from bone marrow and stimulated peripheral blood 470
Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. 469
Leukocyte alkaline-phosphatase score in plasma-cell dyscrasias - correlation with disease severity and circulating levels of granulocyte-colony-stimulating factor 469
Intensive treatment of patients age 60 years and older with de novo acute myeloid leukemia - Analysis of prognostic factors 467
Diagnosis of acute myeloid leukemia and system Coulter VCS 466
Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making 465
Central Nervous System Involvement in Adult Acute Lymphoblastic Leukemia: Diagnostic Tools, Prophylaxis, and Therapy. 465
Identification of emerging FLT3 ITD-positive clones during clinical remission and kinetics of disease relapse in acute myeloid leukaemia with mutated nucleophosmin 462
All-trans retinoic acid (ATRA) administration during pregnancy in relapsed acute promyelocytic leukemia 462
Novel role of triazenes in haematological malignancies: Pilot study of Temozolomide, Lomeguatrib and IL-2 in the chemo-immunotherapy of acute leukaemia 461
Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia 461
Minimally differentiated acute myeloid leukemia (AML-MO): Comparison of 25 cases with other French-American-British subtypes 461
Prognostic relevance of the expression of Tdt and CD7 in 335 cases of acute myeloid leukemia 461
P-glycoprotein and terminal transferase expression identify prognostic subsets within cytogenetic risk classes in acute myeloid leukemia 460
Biological features of acute myeloid leukemia in the elderly 460
Clinical relevance of minimal residual disease detection in adult acute myeloid leukemia 459
Sequential combination of gemtuzumab ozogamicin and standard chemotherapy in older patients with newly diagnosed acute myeloid leukemia: Results of a randomized phase III trial of the EORTC and GIMEMA consortium (AML-17) 458
Efficacy and safety of human leucocyte interferon-alpha treatment in patients younger than 60 years of age with polycythaemia vera 457
Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin's lymphoma 455
Soluble factors levels in the initial staging of high-grade non-Hodgkin's lymphomas 454
O6-(4-Bromothenyl)guanine (PaTrin-2), a novel inhibitor of O6-alkylguanine DNA alkyl-transferase, increases the inhibitory activity of temozolomide against human acute leukaemia cells in vitro 452
High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial 451
P-glycoprotein and BCL-2 levels predict outcome in adult acute lymphoblastic leukaemia 448
Randomized trial of two schedules of low-dose gemtuzumab ozogamicin as induction monotherapy for newly diagnosed acute myeloid leukaemia in older patients not considered candidates for intensive chemotherapy. A phase II study of the EORTC and GIMEMA leukaemia groups (AML-19). 446
Lecam1/Icam1 ratio identifies a distinct pattern on normal and myelodysplastic bone marrow CD34+ progenitors cells 445
AML-M0: a biological and clinical profile 445
Real-life use of erythropoiesis-stimulating agents in myelodysplastic syndromes: a "Gruppo Romano Mielodisplasie (GROM)" multicenter study 443
CD7 Expression in acute myeloid leukemia 441
Biological pattern of AML-M0 versus AML-M1: Response 441
Chromosomal aberration of the 11q23 locus in acute leukemia and frequency of MLL gene translocation: results in 378 adult patients 440
Azacitidine for the treatment of lower risk myelodysplastic syndromes : A retrospective study of 74 patients enrolled in an Italian named patient program. 438
Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage 438
Clinical significance of bax/bcl-2 ratio in chronic lymphocytic leukemia 438
Clinical implication of cytokine and soluble receptor measurements in patients with newly diagnosed aggressive non Hodgkin Lymphomas 434
A haematology consensus agreement on antifungal strategies for neutropenic patients with haematological malignancies and stem cell transplant recipients 434
NK Cell Inflammation in the Clinical Outcome of Colorectal Carcinoma 434
New reciprocal translocation t(6;10) (q27;q11) associated with idiopathic myelofibrosis and eosinophilia 433
Recurrence of a t(8;21)-positive acute myeloid leukemia in the form of a granulocytic sarcoma involving cranial bones: a diagnostic and therapeutic challenge 433
Multidimensional flow cytometry for detection of minimal residual disease in acute myeloid leukemia 432
Advances in the treatment of elderly and frail patients with acute myeloid leukemia 432
Clinical significance of soluble p53 protein in B-cell chronic lymphocytic leukemia 431
Peripheral polyneuropathy during treatment with alpha-2 interferon 431
Minimally differentiated acute myeloid-leukemia (aml-mo): cytochemical, immunophenotypic and cytogenetic analysis of 19 cases 431
First report of t(8;21)(q22;q22) in a case of de novo acute monoblastic leukemia 429
Combination antifungal therapy for invasive mould diseases in haematologic patients. An update on clinical data 428
Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia 428
Blood stem cell processing 427
Contribution of immunophenotypic and genotypic analysis to the diagnosis of acute leukemia 425
Analysis of treatment failure in patients with minimally differentiated acute myeloid leukemia (AML-M0) 425
Red blood cell depletion and cryopreservation of umbilical cord blood (UCB) 423
Role of Minimal (Measurable) Residual Disease Assessment in Older Patients with Acute Myeloid Leukemia 422
All-trans retinoic acid and low dose cytosine arabinoside for the treatment of "poor prognosis" acute myeloid leukemia 421
Cytoplasmic nucleophosmin is not detected in blastic plasmacytoid dendritic cell neoplasm 421
Cytogenetic and molecular diagnostic characterization combined to post-consolidation minimal residual disease assessment by flow-cytometry improves risk stratification in adult acute myeloid leukemia 419
Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. 418
Fluorescence in situ hybridization and conventional cytogenetics for the diagnosis of 11q23(+)/MLL+ translocation in leukaemia 418
Clinical heterogeneity of idiopathic CD4+T lymphocytopenia 418
High interleukin-6 plasma levels in acute promyelocytic leukemia 417
Minimally differentiated acute myeloid leukemia (AML-MO): A distinct clinico-biologic entity with poor prognosis 416
Pretransplant minimal residual disease level predicts clinical outcome in patients with acute myeloid leukemia receiving high-dose chemotherapy and autologous stem cell transplantation 416
P-glycoprotein expression in de novo acute myeloid leukemia 416
In vitro down-regulation of bcl-2 expression by all-trans retinoic acid in AML blasts 416
Azacitidine for the treatment of patients with acute myeloid leukemia 414
GIMEMA AIDA 0493 amended protocol for elderly patients with acute promyelocytic leukaemia. Long-term results and prognostic factors. 413
Thoracic cord compression caused by epidural extramedullary hematopoiesis during erythroid-stimulating agent therapy in two patients with myelodysplastic syndromes 413
Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. 412
Retinoic acid and arsenic trioxide for acute promyelocytic leukemia 412
Quantitative analysis of P-glycoprotein, Bcl-2 and transferrin receptor allows the stratification of acute myeloid leukemia patients within different prognostic risk classes 411
Immunophenotypic analysis in 119 patients with acute myeloid leukemia following a previous malignancy: a comparison with the immunophenotype of 231 de novo cases 410
Role of human leukocyte interferon-alpha in the treatment of patients with polycythemia vera 408
2021 update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party 408
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) 406
Totale 46.127
Salva come PNG Salva come JPEG
Categoria #
all - tutte 222.428
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 222.428
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021589 0 0 0 0 0 0 0 0 0 0 440 149
2021/20222.677 105 308 88 102 77 247 145 164 212 234 207 788
2022/20233.937 414 306 291 410 264 754 469 242 450 70 186 81
2023/20242.233 169 81 199 80 256 549 139 142 98 72 106 342
2024/20257.074 283 1.455 786 402 193 427 548 419 742 625 572 622
2025/202612.492 1.231 623 1.637 1.056 1.335 586 1.486 1.603 1.491 1.312 132 0
Totale 93.553